Click Here to return To Results

 

Placebo-Controlled Multicentre Randomised Trial of Interferon B-1b in Treatment of Secondary Progressive Multiple Sclerosis Lancet 352:1491-1497,1486, European Study Group on Interferon B-1b in Seconda, 1998 See this aricle in Pubmed Article Abstract Interferon B-1b delayed progression for 9-12 months in a study period of 2-3 years. The odds ratio for confirmed progression was 0.65 (95% CI 0.52-0.83). This beneficial effect was seen in patients with superimposed relapses and in patients who had only progressive deterioration without relapses. Positive results were also obtained regarding time to becoming wheelchair-bound, relapse rate and severity, number of steroid treatments and hospital admissions, as well as on magnetic resonance imaging variables. The drug was safe and side effects were in line with previous experience with niterferon B-1b. The study was stopped after the interim results gave clear evidence of efficacy.

Related Tags

(click to filter results - removes previous filter) interferon interferon beta 1-b multiple sclerosis multiple sclerosis,chronic progressive multiple sclerosis,secondary progressive multiple sclerosis,treatment of treatment of neurologic disorder

Click Here to return To Results